Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

rd quarter; and finally, our plans to present the results of all seven cohorts of the INFORM-1 study at the AASLD meeting on November 3."

Results for the Three Months Ended June 30, 2009

InterMune reported total revenue in the second quarter of 2009 of $7.9 million, compared with total revenue of $8.1 million in the second quarter of 2008. Total revenue in the second quarter of 2009 primarily consisted of Actimmune(R) (interferon gamma-1b) revenue of $7.1 million, compared with $7.3 million in the same quarter of 2008, a decrease of approximately 2 percent, reflecting lower off-label physician prescriptions of Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF), which InterMune does not promote.

Research and development (R&D) expenses in the second quarter of 2009 were $22.9 million compared with $25.4 million in the second quarter of 2008, a decrease of approximately 10 percent, reflecting completion of the CAPACITY clinical trials in early 2009, partially offset by expenses associated with the RECAP extension study and the preparation of the NDA and MAA for pirfenidone. General and administrative (G&A) expenses were $8.5 million in the second quarter of 2009, compared with $7.1 million in the same period a year earlier, an increase of approximately 20 percent, primarily attributed to costs related to preparation for the anticipated commercialization of pirfenidone.

InterMune recorded a loss on extinguishment of debt of $9.5 million, of which $8.9 million was non-cash, in the second quarter of 2009 in connection with the April 2009 exchange of approximately $32.3 million of its 0.25% Convertible Senior Notes due 2011 held by certain of its debt holders for shares of the company's common stock. A total of approximately 2.1 million shares of common stock were issued in connection with the transaction.

As of June 30, 2009, InterMune had cash, cash e
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Today, TiFiber, Inc. ... production facility and future company headquarters in Fort ... new materials that safely and effectively control dangerous ... of its historic, strong support for manufacturing, but ... leading edge, technology-based companies such as TiFiber. ...
(Date:12/19/2014)... Biddeford, ME (PRWEB) December 18, 2014 ... founding director of the Center for Excellence in the ... of New England, has been selected as a member ... He is the first neuroscientist from Maine to receive ... a nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... to the rising ageing population and technological innovations ... and nutraceutical industries are catalysing the growth of ... @ http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report ... as well as new entrants/smaller firms to gauge ...
Breaking Biology Technology:Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4
... Mich., Feb. 4 Pfizer,s loss of some ... the gain of two,Michigan companies teaming to help ... myeloma, metastatic bone disease, rheumatoid arthritis and,osteoporosis., ... PhD, announced,his biotechnology company will work with Dr. ...
... Product Candidate Portfolio, - Conference Call Scheduled for 5 ... ... US EST, BRISBANE, Australia, Feb. 4 Progen,Pharmaceuticals Limited ... a Definitive Agreement to acquire privately-held U.S.,oncology company CellGate, Inc. ...
... CHEYENNE, Wyo., Feb. 4 Vestibular Technologies is,pleased ... contract in the physical,therapy products portfolio with Premier ... most prestigious group purchasing organizations,(GPOs)., Owned by ... is a hospital performance improvement alliance serving nearly,1,500 ...
Cached Biology Technology:Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2Progen Expands Drug Development Pipeline Through Acquisition of CellGate 2Progen Expands Drug Development Pipeline Through Acquisition of CellGate 3Progen Expands Drug Development Pipeline Through Acquisition of CellGate 4Progen Expands Drug Development Pipeline Through Acquisition of CellGate 5
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... of the "iPhone 5S Fingerprint Sensor - ... report to their offering. ... of AuthenTec in July 2012, Apple introduced the ... is currently the only device of Apple incorporating ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and ... the addition of the "Samsung Galaxy S5 ... report to their offering. ... a totally different sensing technology than the iPhone ... fingerprint sensor in its product. The ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... MD FASEB MARC (Maximizing Access to Research Careers) ... American College of Sports Medicine (ACSM) Texas Regional Chapter ... These awards are meant to promote the entry of ... the mainstream of the basic science community and to ...
... cross the Atlantic Ocean to get to the Sargasso Sea to ... them from predators, researchers from the University of Southern Denmark report: ... The European eel is in decline, and all over the world ... to bring its numbers back up. One of the great puzzles ...
... Medical Research have glimpsed two proteins working together inside ... and its exterior compartment, the cytoplasm. The research provides ... found in organisms from yeast to humans does its ... Sue Jaspersen, Ph.D., focused on a protein called Ndc1, ...
Cached Biology News:Threatened eels disappear in the deep on their way to the Sargasso Sea 2Conserved nuclear envelope protein uses a shuttle service to travel between job sites 2Conserved nuclear envelope protein uses a shuttle service to travel between job sites 3
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Biology Products: